US4994467A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treating autism and other developmental disorders in children with NMDA receptor antagonists
Assignee: Individual
•
Filing: 1989-05-31
•
Granted: 1991-02-19
•
Expires: 2009-05-31
Abstract
Abstract A method is provided for treating autism and other pervasive developmental disorders in children by the administration of a therapeutically effective amount of a N-methyl-D-aspartate (NMDA) receptor antagonist. The NMDA receptor antagonist is chosen from the group consisting of ketamine and dextromethorphan.
Inventors
- 👤 Andrew W. Zimmerman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 12:25
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/485; A61K31/13; A61K31/135
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
47 words
A method of treating autism and other pervasive developmental disorders in children comprising the administration to said children of a therapeutically effective amount of a N-methyl-D-aspartate receptor antagonist chosen from the group consisting of ketamine, a pharmaceutically acceptable salt thereof, dextromethorphan and a pharmaceutically acceptable salt thereof.
Claim 2
Independent Claim
47 words
A method of treating autism and other pervasive developmental disorders in children comprising the administration to said children of a therapeutically effective amount of a N-methyl-D-aspartate receptor antagonist chosen from the group consisting of ketamine, a pharmaceutically acceptable salt thereof, dextromethorphan and a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
22 words
The method of claim 1 wherein said antagonist is chosen from the group consisting of ketamine and a pharmaceutically effective salt thereof.
Claim 4
Dependent Claim
13 words
The method of claim 2 wherein said antagonist is administered intramuscularly and intravenously.
Claim 5
Dependent Claim
49 words
The method of claim 3 wherein about 40 mg of said antagonist is administered intramuscularly over a period of time of less than about 1 minute and about 200 mg of said antagonist is administered over a period of time of from about 90 minutes to about 120 minutes.
Claim 6
Dependent Claim
22 words
The method of claim 1 wherein said antagonist is chosen from the group consisting of dextromethorphan and a pharmaceutically effective salt thereof.
Claim 7
Dependent Claim
11 words
The method of claim 5 wherein said antagonist is administered orally.
Claim 8
Dependent Claim
27 words
The method of claim 6 wherein said antagonist is administered in a dose of from about 0.5 mg/kg to about 3.0 mg/kg of body weight per day.
References Cited (Backward Citations)
US3932623A
Cited
US4778794A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-02-18 | 1994-08-20 | 1995-02-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-02-18 | 1998-08-20 | 1999-02-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-02-18 | 2002-08-20 | 2003-02-19 | $7700.00 | Window Closed / Lapsed |